TY - JOUR
T1 - Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"
AU - Veeraraghavalu, Karthikeyan
AU - Zhang, Can
AU - Miller, Sean
AU - Hefendehl, Jasmin K.
AU - Rajapaksha, Tharinda W.
AU - Ulrich, Jason
AU - Jucker, Mathias
AU - Holtzman, David M.
AU - Tanzi, Rudolph E.
AU - Vassar, Robert
AU - Sisodia, Sangram S.
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) reported that bexarotene rapidly reduces β-amyloid (Aβ) levels and plaque burden in two mouse models of Aβ deposition in Alzheimer's disease (AD). We now report that, although bexarotene reduces soluble Aβ40 levels in one of the mouse models, the drug has no impact on plaque burden in three strains that exhibit Aβ amyloidosis.
AB - Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) reported that bexarotene rapidly reduces β-amyloid (Aβ) levels and plaque burden in two mouse models of Aβ deposition in Alzheimer's disease (AD). We now report that, although bexarotene reduces soluble Aβ40 levels in one of the mouse models, the drug has no impact on plaque burden in three strains that exhibit Aβ amyloidosis.
UR - http://www.scopus.com/inward/record.url?scp=84877946097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877946097&partnerID=8YFLogxK
U2 - 10.1126/science.1235505
DO - 10.1126/science.1235505
M3 - Comment/debate
C2 - 23704555
AN - SCOPUS:84877946097
SN - 0036-8075
VL - 340
JO - Science
JF - Science
IS - 6135
ER -